Key result
Several classes of nucleoside analogues exhibited moderate antiviral activity against SARS-CoV in Vero 76 cells.
Why the study?
Do nucleoside analogues exhibit antiviral activity against SARS-CoV in Vero 76 cells?
Do nucleoside analogues exhibit antiviral activity against SARS-CoV in Vero 76 cells?
Several classes of nucleoside analogues demonstrate moderate in vitro antiviral activity against SARS-CoV.
Moderate in vitro activity against SARS-CoV is hypothesis-generating; leaves open in vivo efficacy and clinical translation.
The recent outbreak of severe acute respiratory syndrome (SARS), which is an acute respiratory illness, is caused by newly discovered SARS coronavirus (SARS-CoV). Herein we describe the antiviral activity of several classes of nucleoside analogues evaluated against SARS-CoV in Vero 76 cells, some of which exhibited moderate activity.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2006) studied this question. Several classes of nucleoside analogues exhibited moderate antiviral activity against SARS-CoV in Vero 76 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: